SEC Form 4 · accession 0000911916-17-000034
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas P. Mathers
Officer — Chief Executive Officer · Director
Period of report
Jan 5, 2017
Accepted (ET)
Jan 5, 2017 · 4:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 5, 2017 | M | 3,755 | — | A | 258,021 | D | |
| Common StockF2,F3 | Jan 5, 2017 | S | 802 | $34.2462 | D | 257,219 | D | |
| Common StockF2,F4 | Jan 5, 2017 | S | 200 | $34.8625 | D | 257,019 | D | |
| Common StockF2 | Jan 5, 2017 | S | 500 | $35.60 | D | 256,519 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F5 | — | Jan 5, 2017 | M | 3,755 | D | — | — | Common Stock | 3,755 | 105,147 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of CoLucid Pharmaceuticals, Inc. common stock.
- F2Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016. The purpose of the plan was to sell shares of common stock in order to pay the taxes related to the settlement of the RSUs.
- F3Represents the sale of 802 shares in multiple transactions, ranging in price from $33.45 to $34.40 per share, resulting in a weighted average sale price of $34.2462. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F4Represents the sale of 200 shares in multiple transactions, ranging in price from $34.50 to $35.225 per share, resulting in a weighted average sale price of $34.8625. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F5On May 5, 2015, the reporting person received 360,508 RSUs. Those RSUs vest as follows: 50% of the RSUs vested on November 5, 2015; 12.5% of the RSUs vested on May 5, 2016; and the remaining RSUs vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.